Canaccord Genuity Keeps Their Buy Rating on Seres Therapeutics (MCRB)
I'm PortAI, I can summarize articles.
Canaccord Genuity analyst John Newman has reaffirmed a Buy rating on Seres Therapeutics (MCRB) with a price target of $22.00. The overall analyst consensus for Seres Therapeutics is a Moderate Buy, also with a $22.00 average price target. Newman has an average return of -1.6% and a success rate of 36.60%, covering the Healthcare sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments